<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28973916</article-id>
<article-id pub-id-type="pmc">5651774</article-id>
<article-id pub-id-type="publisher-id">201711351</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1711351114</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Neuroscience</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome</article-title>
<alt-title alt-title-type="short">Cannabidiol in a mouse model of Dravet syndrome</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kaplan</surname>
<given-names>Joshua S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stella</surname>
<given-names>Nephi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Catterall</surname>
<given-names>William A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Westenbroek</surname>
<given-names>Ruth E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Department of Pharmacology, <institution>University of Washington</institution>, Seattle, <addr-line>WA</addr-line> 98195;</aff>
<aff id="aff2"><sup>b</sup>Department of Psychiatry and Behavioral Sciences, <institution>University of Washington</institution>, Seattle, <addr-line>WA</addr-line> 98195</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>2</sup>To whom correspondence should be addressed. Email: <email>wcatt@uw.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by William A. Catterall, September 7, 2017 (sent for review July 3, 2017; reviewed by Lori L. Isom, Daniele Piomelli, and Peter C. Ruben)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: J.S.K., N.S., W.A.C., and R.E.W. designed research; J.S.K. and R.E.W. performed research; J.S.K., N.S., W.A.C., and R.E.W. analyzed data; and J.S.K., N.S., W.A.C., and R.E.W. wrote the paper.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: L.L.I., University of Michigan Medical School; D.P., University of California, Irvine; and P.C.R., Simon Fraser University.</p>
</fn>
<fn fn-type="equal" id="fn1">
<p><sup>1</sup>N.S., W.A.C., and R.E.W. contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement">
<p>The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>17</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>2</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>114</volume>
<issue>42</issue>
<fpage>11229</fpage>
<lpage>11234</lpage>
<permissions></permissions>
<self-uri xlink:href="pnas.201711351.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Medicinal cannabis use is booming despite limited preclinical evidence and mechanistic insight. Recent clinical trials of cannabidiol (CBD) in Dravet syndrome (DS) support its clinical efficacy for reduction of seizure frequency and invite study of its benefits for additional DS symptoms. We demonstrate here that treatment with CBD is beneficial for seizure frequency, duration, and severity and for autistic-like social deficits in a mouse model of DS. CBD rescue of DS symptoms is associated with increased inhibitory neurotransmission, potentially mediated by antagonism of the lipid-activated G protein-coupled receptor GPR55. These studies lend critical support for treatment of seizures in DS with CBD, extend the scope of CBD treatment to autistic-like behaviors, and provide initial mechanistic insights into CBDâ€™s therapeutic actions.</p>
</abstract>
<abstract>
<p>Worldwide medicinal use of cannabis is rapidly escalating, despite limited evidence of its efficacy from preclinical and clinical studies. Here we show that cannabidiol (CBD) effectively reduced seizures and autistic-like social deficits in a well-validated mouse genetic model of Dravet syndrome (DS), a severe childhood epilepsy disorder caused by loss-of-function mutations in the brain voltage-gated sodium channel Na<sub>V</sub>1.1. The duration and severity of thermally induced seizures and the frequency of spontaneous seizures were substantially decreased. Treatment with lower doses of CBD also improved autistic-like social interaction deficits in DS mice. Phenotypic rescue was associated with restoration of the excitability of inhibitory interneurons in the hippocampal dentate gyrus, an important area for seizure propagation. Reduced excitability of dentate granule neurons in response to strong depolarizing stimuli was also observed. The beneficial effects of CBD on inhibitory neurotransmission were mimicked and occluded by an antagonist of GPR55, suggesting that therapeutic effects of CBD are mediated through this lipid-activated G protein-coupled receptor. Our results provide critical preclinical evidence supporting treatment of epilepsy and autistic-like behaviors linked to DS with CBD. We also introduce antagonism of GPR55 as a potential therapeutic approach by illustrating its beneficial effects in DS mice. Our study provides essential preclinical evidence needed to build a sound scientific basis for increased medicinal use of CBD.</p>
</abstract>
<kwd-group>
<kwd>cannabidiol</kwd>
<kwd>Dravet syndrome</kwd>
<kwd>epilepsy</kwd>
<kwd>autism</kwd>
<kwd>
<italic>Scn1a</italic>
</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">Citizens United for Research in Epilepsy (CURE)<named-content content-type="funder-id">100002736</named-content></funding-source>
<award-id rid="sp1">NA</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">HHS | NIH | National Institute on Drug Abuse (NIDA)<named-content content-type="funder-id">100000026</named-content></funding-source>
<award-id rid="sp2">R01 DA026430</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)<named-content content-type="funder-id">100000065</named-content></funding-source>
<award-id rid="sp3">R01 NS025704</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="6"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>